Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04096638 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by invoX Pharma Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT04096638 is a Phase 1 study that has completed, run by invoX Pharma Limited. The registered enrollment target is 61 participants.
The verdict
NCT04096638, a Phase 1 study, has completed, sponsored by invoX Pharma Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
A Phase 1a/1b, multicenter, open-label, non-randomized, dose-escalation, and cohort expansion study to examine the DLTs, MTD, and RP2D of SB 11285 administered as an IV infusion in patients with advanced solid tumors.
Interventions
- DRUG Atezolizumab
- DRUG SB 11285
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2024-07-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04096638
The ClinicalTrials.gov registry entry for NCT04096638 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is invoX Pharma Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT04096638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04096638 about?
NCT04096638 is a clinical study titled "Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors". A Phase 1a/1b, multicenter, open-label, non-randomized, dose-escalation, and cohort expansion study to examine the DLTs, MTD, and RP2D of SB 11285 administered as an IV infusion in patients with advanced solid tumors.
What is the current status of trial NCT04096638?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2019-09-23. Estimated completion is 2024-07-16.
What interventions are being tested in trial NCT04096638?
The interventions under investigation include: Atezolizumab (DRUG), SB 11285 (DRUG).
Who is sponsoring clinical trial NCT04096638?
This trial is sponsored by invoX Pharma Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.